Brief: X4 Pharmaceuticals Announces EMA Validation Of Marketing Authorization Application
24/01/2025 12:55
Jan 24 (Reuters) - X4 Pharmaceuticals Inc XFOR.O :
* X4 PHARMACEUTICALS ANNOUNCES EMA VALIDATION OF MARKETING
AUTHORIZATION APPLICATION (MAA) FOR MAVORIXAFOR FOR THE
TREATMENT OF WHIM SYNDROME
* X4 PHARMACEUTICALS INC - DECISION ON MAVORIXAFOR MAA
EXPECTED IN
1H 2026
* X4 PHARMACEUTICALS INC: DECISION ON MAA EXPECTED IN 1H
2026
Source text: ID:nGNXbQj78L
Further company coverage: XFOR.O
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule